Intellia Therapeutics analyst ratings
Intellia Therapeutics analyst ratings
Intellia治療公司分析師評級
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 05/09/2022 | 131.24% | JMP Securities | $165 → $110 | Maintains | Market Outperform |
| 05/06/2022 | 106.01% | Credit Suisse | $100 → $98 | Maintains | Outperform |
| 05/06/2022 | 120.73% | Raymond James | $181 → $105 | Maintains | Outperform |
| 04/28/2022 | 110.22% | Credit Suisse | → $100 | Initiates Coverage On | → Outperform |
| 03/07/2022 | 91.3% | Brookline Capital | → $91 | Upgrades | Hold → Buy |
| 03/01/2022 | 261.57% | Chardan Capital | $177 → $172 | Maintains | Buy |
| 02/18/2022 | — | William Blair | Initiates Coverage On | → Outperform | |
| 02/14/2022 | — | Brookline Capital | Initiates Coverage On | → Hold | |
| 02/07/2022 | 215.32% | Oppenheimer | $145 → $150 | Upgrades | Perform → Outperform |
| 01/31/2022 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 01/07/2022 | 246.86% | JMP Securities | $175 → $165 | Maintains | Market Outperform |
| 01/07/2022 | 259.47% | Piper Sandler | → $171 | Initiates Coverage On | → Overweight |
| 11/05/2021 | 204.81% | Oppenheimer | $160 → $145 | Maintains | Perform |
| 11/05/2021 | 282.59% | HC Wainwright & Co. | $171 → $182 | Maintains | Buy |
| 10/05/2021 | 257.37% | Guggenheim | → $170 | Initiates Coverage On | → Buy |
| 09/24/2021 | 263.67% | Stifel | → $173 | Initiates Coverage On | → Buy |
| 08/06/2021 | 280.49% | Raymond James | $168 → $181 | Maintains | Outperform |
| 08/06/2021 | 267.88% | JMP Securities | $160 → $175 | Maintains | Market Outperform |
| 08/06/2021 | 236.35% | Oppenheimer | $125 → $160 | Maintains | Perform |
| 08/06/2021 | 429.75% | Goldman Sachs | $225 → $252 | Maintains | Buy |
| 08/06/2021 | 272.08% | Chardan Capital | $130 → $177 | Maintains | Buy |
| 06/29/2021 | 162.77% | Oppenheimer | $73 → $125 | Maintains | Perform |
| 06/29/2021 | 253.16% | Raymond James | $106 → $168 | Maintains | Outperform |
| 06/28/2021 | 82.89% | Wedbush | $73 → $87 | Maintains | Neutral |
| 06/28/2021 | 181.69% | Barclays | $88 → $134 | Maintains | Overweight |
| 06/28/2021 | 242.65% | Goldman Sachs | $115 → $163 | Maintains | Buy |
| 06/28/2021 | 236.35% | Truist Securities | $80 → $160 | Maintains | Buy |
| 06/28/2021 | 131.24% | Roth Capital | $80 → $110 | Maintains | Buy |
| 06/28/2021 | 259.47% | HC Wainwright & Co. | $111 → $171 | Maintains | Buy |
| 06/28/2021 | 173.28% | Chardan Capital | $85 → $130 | Maintains | Buy |
| 06/23/2021 | 84.99% | JMP Securities | $80 → $88 | Maintains | Market Outperform |
| 06/23/2021 | 78.68% | Baird | $60 → $85 | Maintains | Neutral |
| 06/11/2021 | 133.34% | HC Wainwright & Co. | → $111 | Initiates Coverage On | → Buy |
| 05/07/2021 | 68.17% | Roth Capital | $75 → $80 | Upgrades | Neutral → Buy |
| 05/04/2021 | 131.24% | RBC Capital | → $110 | Initiates Coverage On | → Outperform |
| 03/04/2021 | 68.17% | JMP Securities | → $80 | Initiates Coverage On | → Outperform |
| 02/10/2021 | 78.68% | Chardan Capital | $57.5 → $85 | Maintains | Buy |
| 01/08/2021 | 122.83% | Raymond James | $39 → $106 | Maintains | Outperform |
| 12/22/2020 | — | Baird | Downgrades | Outperform → Neutral | |
| 10/27/2020 | -15.91% | Truist Securities | → $40 | Initiates Coverage On | → Buy |
| 10/14/2020 | — | Wells Fargo | Initiates Coverage On | → Overweight | |
| 09/18/2020 | -30.63% | Goldman Sachs | → $33 | Initiates Coverage On | → Buy |
| 06/02/2020 | -55.85% | Credit Suisse | $19 → $21 | Maintains | Neutral |
| 02/28/2020 | — | Oppenheimer | Upgrades | Perform → Outperform | |
| 02/14/2020 | -66.37% | Wedbush | $21 → $16 | Downgrades | Outperform → Neutral |
| 11/01/2019 | -49.55% | Raymond James | → $24 | Upgrades | Market Perform → Outperform |
| 07/09/2019 | -51.65% | Baird | → $23 | Initiates Coverage On | → Outperform |
| 06/10/2019 | -66.37% | Roth Capital | → $16 | Initiates Coverage On | → Neutral |
| 05/03/2019 | — | Wedbush | Upgrades | Neutral → Outperform | |
| 05/03/2019 | — | Wedbush | Upgrades | Neutral → Outperform | |
| 04/12/2019 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 02/08/2019 | -57.96% | BTIG | → $20 | Initiates Coverage On | → Buy |
| 11/28/2018 | -51.65% | Leerink Swann | → $23 | Initiates Coverage On | → Outperform |
| 11/02/2018 | -57.96% | Wedbush | $36 → $20 | Downgrades | Outperform → Neutral |
| 09/21/2018 | — | Raymond James | Initiates Coverage On | → Market Perform | |
| 05/15/2018 | — | Chardan Capital | Upgrades | Neutral → Buy | |
| 03/08/2018 | 59.76% | JMP Securities | → $76 | Initiates Coverage On | → Market Outperform |
| 03/07/2018 | -3.3% | Barclays | $33 → $46 | Maintains | Overweight |
| 11/03/2017 | -41.14% | Credit Suisse | $24 → $28 | Maintains | Outperform |
| 11/01/2017 | -11.71% | Jefferies | $36 → $42 | Maintains | Buy |
| 09/07/2017 | -39.04% | Barclays | → $29 | Initiates Coverage On | → Overweight |
| 08/29/2017 | — | Chardan Capital | Downgrades | Buy → Neutral | |
| 08/02/2017 | -57.96% | Chardan Capital | $19 → $20 | Maintains | Buy |
| 07/18/2017 | — | Oppenheimer | Initiates Coverage On | → Perform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 05/09/2022 | 131.24% | JMP證券 | $165 → $110 | 維護 | 市場表現強於大盤 |
| 05/06/2022 | 106.01% | 瑞士信貸 | $100 → $98 | 維護 | 跑贏大盤 |
| 05/06/2022 | 120.73% | 雷蒙德·詹姆斯 | $181 → $105 | 維護 | 跑贏大盤 |
| 04/28/2022 | 110.22% | 瑞士信貸 | → $100 | 開始承保 | →跑贏大盤 |
| 03/07/2022 | 91.3% | 布魯克林資本 | → $91 | 升級 | 持有→購買 |
| 03/01/2022 | 261.57% | 查爾丹資本 | $177 → $172 | 維護 | 買 |
| 02/18/2022 | — | 威廉·布萊爾 | 開始承保 | →跑贏大盤 | |
| 02/14/2022 | — | 布魯克林資本 | 開始承保 | →保留 | |
| 02/07/2022 | 215.32% | 奧本海默 | $145 → $150 | 升級 | →表現強於大盤 |
| 01/31/2022 | — | 考恩公司 | 開始承保 | →跑贏大盤 | |
| 01/07/2022 | 246.86% | JMP證券 | $175 → $165 | 維護 | 市場表現強於大盤 |
| 01/07/2022 | 259.47% | 派珀·桑德勒 | → $171 | 開始承保 | →超重 |
| 11/05/2021 | 204.81% | 奧本海默 | $160 → $145 | 維護 | 執行 |
| 11/05/2021 | 282.59% | HC Wainwright公司 | $171 → $182 | 維護 | 買 |
| 10/05/2021 | 257.37% | 古根海姆 | → $170 | 開始承保 | →購買 |
| 09/24/2021 | 263.67% | Stifel | → $173 | 開始承保 | →購買 |
| 08/06/2021 | 280.49% | 雷蒙德·詹姆斯 | $168 → $181 | 維護 | 跑贏大盤 |
| 08/06/2021 | 267.88% | JMP證券 | $160 → $175 | 維護 | 市場表現強於大盤 |
| 08/06/2021 | 236.35% | 奧本海默 | $125 → $160 | 維護 | 執行 |
| 08/06/2021 | 429.75% | 高盛 | $225 → $252 | 維護 | 買 |
| 08/06/2021 | 272.08% | 查爾丹資本 | $130 → $177 | 維護 | 買 |
| 06/29/2021 | 162.77% | 奧本海默 | $73 → $125 | 維護 | 執行 |
| 06/29/2021 | 253.16% | 雷蒙德·詹姆斯 | $106 → $168 | 維護 | 跑贏大盤 |
| 06/28/2021 | 82.89% | 韋德布什 | $73 → $87 | 維護 | 中性 |
| 06/28/2021 | 181.69% | 巴克萊 | $88 → $134 | 維護 | 超重 |
| 06/28/2021 | 242.65% | 高盛 | $115 → $163 | 維護 | 買 |
| 06/28/2021 | 236.35% | Truist證券 | $80 → $160 | 維護 | 買 |
| 06/28/2021 | 131.24% | 羅斯資本 | $80 → $110 | 維護 | 買 |
| 06/28/2021 | 259.47% | HC Wainwright公司 | $111 → $171 | 維護 | 買 |
| 06/28/2021 | 173.28% | 查爾丹資本 | $85 → $130 | 維護 | 買 |
| 06/23/2021 | 84.99% | JMP證券 | $80 → $88 | 維護 | 市場表現強於大盤 |
| 06/23/2021 | 78.68% | 貝爾德 | $60 → $85 | 維護 | 中性 |
| 06/11/2021 | 133.34% | HC Wainwright公司 | → $111 | 開始承保 | →購買 |
| 05/07/2021 | 68.17% | 羅斯資本 | $75 → $80 | 升級 | 中性→購買 |
| 05/04/2021 | 131.24% | 加拿大皇家銀行資本 | → $110 | 開始承保 | →跑贏大盤 |
| 03/04/2021 | 68.17% | JMP證券 | → $80 | 開始承保 | →跑贏大盤 |
| 02/10/2021 | 78.68% | 查爾丹資本 | $57.5 → $85 | 維護 | 買 |
| 01/08/2021 | 122.83% | 雷蒙德·詹姆斯 | $39 → $106 | 維護 | 跑贏大盤 |
| 12/22/2020 | — | 貝爾德 | 評級下調 | 跑贏→中性 | |
| 10/27/2020 | -15.91% | Truist證券 | → $40 | 開始承保 | →購買 |
| 10/14/2020 | — | 富國銀行(Wells Fargo) | 開始承保 | →超重 | |
| 09/18/2020 | -30.63% | 高盛 | → $33 | 開始承保 | →購買 |
| 06/02/2020 | -55.85% | 瑞士信貸 | $19 → $21 | 維護 | 中性 |
| 02/28/2020 | — | 奧本海默 | 升級 | →表現強於大盤 | |
| 02/14/2020 | -66.37% | 韋德布什 | $21 → $16 | 評級下調 | 跑贏→中性 |
| 11/01/2019 | -49.55% | 雷蒙德·詹姆斯 | → $24 | 升級 | 市場表現優於→ |
| 07/09/2019 | -51.65% | 貝爾德 | → $23 | 開始承保 | →跑贏大盤 |
| 06/10/2019 | -66.37% | 羅斯資本 | → $16 | 開始承保 | →中性 |
| 05/03/2019 | — | 韋德布什 | 升級 | 中性→表現優異 | |
| 05/03/2019 | — | 韋德布什 | 升級 | 中性→表現優異 | |
| 04/12/2019 | — | Evercore ISI集團 | 開始承保 | →跑贏大盤 | |
| 02/08/2019 | -57.96% | BTIG | → $20 | 開始承保 | →購買 |
| 11/28/2018 | -51.65% | 利林克·斯旺 | → $23 | 開始承保 | →跑贏大盤 |
| 11/02/2018 | -57.96% | 韋德布什 | $36 → $20 | 評級下調 | 跑贏→中性 |
| 09/21/2018 | — | 雷蒙德·詹姆斯 | 開始承保 | →市場表現 | |
| 05/15/2018 | — | 查爾丹資本 | 升級 | 中性→購買 | |
| 03/08/2018 | 59.76% | JMP證券 | → $76 | 開始承保 | →市場跑贏大盤 |
| 03/07/2018 | -3.3% | 巴克萊 | $33 → $46 | 維護 | 超重 |
| 11/03/2017 | -41.14% | 瑞士信貸 | $24 → $28 | 維護 | 跑贏大盤 |
| 11/01/2017 | -11.71% | 傑富瑞 | $36 → $42 | 維護 | 買 |
| 09/07/2017 | -39.04% | 巴克萊 | → $29 | 開始承保 | →超重 |
| 08/29/2017 | — | 查爾丹資本 | 評級下調 | 購買→中性 | |
| 08/02/2017 | -57.96% | 查爾丹資本 | $19 → $20 | 維護 | 買 |
| 07/18/2017 | — | 奧本海默 | 開始承保 | →性能 |
Data brought to you by Benzinga APIs
Benzinga API為您帶來的數據
Intellia Therapeutics Questions & Answers
Intellia Treateutics問答
What is the target price for Intellia Therapeutics (NTLA)?
Intellia治療公司(NTLA)的目標價格是多少？
The latest price target for Intellia Therapeutics (NASDAQ: NTLA) was reported by Credit Suisse on May 6, 2022. The analyst firm set a price target for $98.00 expecting NTLA to rise to within 12 months (a possible 106.01% upside). 32 analyst firms have reported ratings in the last year.
瑞士信貸於2022年5月6日報告了Intellia治療公司(納斯達克：NTLA)的最新目標價。這家分析公司將目標價定為98美元，預計NTLA將在12個月內上漲至(可能上漲106.01%)。去年有32家分析公司公佈了評級。
What is the most recent analyst rating for Intellia Therapeutics (NTLA)?
Intellia治療公司(NTLA)的最新分析師評級是多少？
The latest analyst rating for Intellia Therapeutics (NASDAQ: NTLA) was provided by Credit Suisse, and Intellia Therapeutics maintained their outperform rating.
對英特利亞治療公司(納斯達克代碼：NTLA)的最新分析師評級是由瑞士信貸提供的，英特利亞治療公司維持其表現優於大盤的評級。
When is the next analyst rating going to be posted or updated for Intellia Therapeutics (NTLA)?
Intellia Treeutics(NTLA)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Intellia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Intellia Therapeutics was filed on May 6, 2022 so you should expect the next rating to be made available sometime around May 6, 2023.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閲公共財務報表，與Intellia治療公司的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Intellia治療公司的上一次評級是在2022年5月6日提交的，所以你應該預計下一次評級將在2023年5月6日左右的某個時候提供。
Is the Analyst Rating Intellia Therapeutics (NTLA) correct?
分析師對Intellia Treateutics(NTLA)的評級正確嗎？
While ratings are subjective and will change, the latest Intellia Therapeutics (NTLA) rating was a maintained with a price target of $100.00 to $98.00. The current price Intellia Therapeutics (NTLA) is trading at is $47.57, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Intellia治療公司(NTLA)的評級保持不變，目標價在100.00美元至98.00美元之間。Intellia治療公司(NTLA)目前的交易價格為47.57美元，超出了分析師的預測範圍。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。